Myelofibrosis
Myelofibrosis is a type of blood cancer that disrupts the body's normal production of blood cells, leading to severe anemia, fatigue, and an enlarged spleen.
Myelofibrosis: INCB057643 Safety Study
We are testing a new drug, INCB057643, for people with myelofibrosis and other advanced blood cancers. The study focuses on understanding its safety and how well patients tolerate it.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Myeloproliferative Neoplasm
Myeloproliferative neoplasms are a group of disorders caused by the overproduction of blood cells in the bone marrow, which can lead to complications like blood clots and bleeding.
Myelodysplastic Syndrome
Myelodysplastic syndrome is a group of disorders caused by poorly formed or dysfunctional blood cells, leading to symptoms like fatigue, frequent infections, and easy bleeding.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Helsinki University Central Hospital
Department of Hematology
Helsinki, Finland
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Dpt of Clinical and Biological Sciences
Beinasco, Italy
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Complex Operational Unit (UOC) Hematology - Via G. Massarenti 9 40138 Bologna Italy
Bologna, Italy
Sponsor: Incyte Corp.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.